Albumin-to-alkaline Phosphatase Ratio May Be a Better Predictor of Survival Than Sclerostin, Dickkopf-1, Osteopontin, Osteoprotegerin and Osteocalcin

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 22

PMID 38644839

Authors

K Mathold

R Nobin

L Brudin

M Carlsson

P Wanby

Affiliations

Soon will be listed here.

Abstract

Objectives: The value of biochemical markers of bone turnover (BTMs) in predicting survival and disease remains unclear. In a prospective study we evaluated the novel biomarkers for bone turnover sclerostin, dickkopf-1 (DKK-1), osteopontin (OPN), osteoprotegerin (OPG) and osteocalcin (OC), as well as a traditional biomarker, alkaline phosphatase (ALP) in relation to risk of mortality, cardiovascular events and fractures.

Participants: and Methods:Routine blood tests and serum BTMs, including ALP, were analyzed in patients with hip fracture n = 97, stroke n = 71 and healthy volunteers n = 83 (mean age 86, 83 and 77, respectively), followed for 7 years. Hazard Ratios (HR) were calculated for mortality, cardiovascular events and fractures in relation to these biomarkers. After adding the albumin-to-ALP ratio (AAPR) a post hoc analysis was performed.

Results: 120 participants died during the study. In the entire group of patients and volunteers (n = 251) higher AAPR (HR 0.28, 95 % CI 0.14-0.59, p < 0.001) was associated with decreased mortality. OPN and OPG were associated with mortality risk only in the univariate statistical analysis. HR for high AAPR in relation to new cardiovascular events was borderline significant (HR 0.29, 95 % CI 0.08-1.06, p = 0.061). None of the examined biomarkers were associated with new fractures, nor with an increased risk of a new cardiovascular event.

Conclusions: AAPR may be a better predictor of mortality than the more novel BTMs, and higher AAPR could be associated with longer life expectancy. Further studies should determine the clinical usefulness of AAPR as a biomarker of mortality and cardiovascular disease.

References

Mathold K, Wanby P, Brudin L, Von S, Carlsson M . Alterations in bone turnover markers in patients with noncardio-embolic ischemic stroke. PLoS One. 2018; 13(11):e0207348. PMC: 6264871. DOI: 10.1371/journal.pone.0207348. View

Zhu Z, Guo D, Zhong C, Wang A, Xie X, Xu T . Serum Dkk-1 (Dickkopf-1) Is a Potential Biomarker in the Prediction of Clinical Outcomes Among Patients With Acute Ischemic Stroke. Arterioscler Thromb Vasc Biol. 2018; 39(2):285-293. DOI: 10.1161/ATVBAHA.118.311960. View

Park J, Kang D, Yang H, Cho H, Park K, Lee H . Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur Heart J. 2012; 34(12):920-31. DOI: 10.1093/eurheartj/ehs419. View

Lv F, Cai X, Yang W, Gao L, Chen L, Wu J . Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 2019; 130:115121. DOI: 10.1016/j.bone.2019.115121. View

Cheung B, Ong K, Cheung R, Wong L, Wat N, Tam S . Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med. 2008; 46(4):523-7. DOI: 10.1515/CCLM.2008.111. View

Huang Q, Li J, Huang X, Jiang L, Huang L, An H . Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis. Int J Med Sci. 2019; 16(10):1328-1337. PMC: 6818186. DOI: 10.7150/ijms.34274. View

Dovjak P, Dorfer S, Foger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P . Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014; 60(6):493-501. DOI: 10.1159/000358303. View

Kosmopoulos M, Paschou S, Grapsa J, Anagnostis P, Vryonidou A, Goulis D . The Emerging Role of Bone Markers in Diagnosis and Risk Stratification of Patients With Coronary Artery Disease. Angiology. 2019; 70(8):690-700. DOI: 10.1177/0003319718822625. View

Kim S, McClave S, Martindale R, Miller K, Hurt R . Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship?. Am Surg. 2017; 83(11):1220-1227. DOI: 10.1177/000313481708301123. View

10.

Rahmani J, Miri A, Namjoo I, Zamaninour N, Maljaei M, Zhou K . Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. Eur J Gastroenterol Hepatol. 2019; 31(5):555-562. DOI: 10.1097/MEG.0000000000001353. View

11.

Oye-Somefun A, Kuk J, Ardern C . Associations between elevated kidney and liver biomarker ratios, metabolic syndrome and all-cause and coronary heart disease (CHD) mortality: analysis of the U.S. National Health and Nutrition Examination Survey (NHANES). BMC Cardiovasc Disord. 2021; 21(1):352. PMC: 8311936. DOI: 10.1186/s12872-021-02160-w. View

12.

Hlaing T, Compston J . Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem. 2014; 51(Pt 2):189-202. DOI: 10.1177/0004563213515190. View

13.

Browner W, Lui L, Cummings S . Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86(2):631-7. DOI: 10.1210/jcem.86.2.7192. View

14.

Tschiderer L, Klingenschmid G, Nagrani R, Willeit J, Laukkanen J, Schett G . Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants. J Am Heart Assoc. 2018; 7(16):e009012. PMC: 6201389. DOI: 10.1161/JAHA.118.009012. View

15.

Valentini A, Cianfarani M, Tarantino U, Di Daniele N, Bertoli A . Osteoprotegerin as a biomarker of geriatric frailty syndrome. Aging (Albany NY). 2019; 11(14):4900-4909. PMC: 6682533. DOI: 10.18632/aging.102083. View

16.

Wanby P, Nobin R, Von S, Brudin L, Carlsson M . Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls. J Endocrinol Invest. 2016; 39(8):855-63. DOI: 10.1007/s40618-015-0421-5. View

17.

Singh A, Gill G, Kaur H, Amhmed M, Jakhu H . Role of osteopontin in bone remodeling and orthodontic tooth movement: a review. Prog Orthod. 2018; 19(1):18. PMC: 6015792. DOI: 10.1186/s40510-018-0216-2. View

18.

Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P . Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33(3):209-90. DOI: 10.1016/j.mam.2011.12.002. View

19.

Henriksen K, Christiansen C, Karsdal M . Role of biochemical markers in the management of osteoporosis. Climacteric. 2015; 18 Suppl 2:10-8. DOI: 10.3109/13697137.2015.1101256. View

20.

Kim J, Liu X, Wang J, Chen X, Zhang H, Kim S . Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 2013; 5(1):13-31. PMC: 3582304. DOI: 10.1177/1759720X12466608. View